Literature DB >> 30773217

Dendritic cell line AP284 supports Th17 amplification.

Pollyana Guimarães de Oliveira1, Clayson Moura Gomes2, Lucilla Ribeiro Ávila3, Fatima Ribeiro-Dias1, Pieter Johannes Maria Leenen4, Milton Adriano Pelli de Oliveira5.   

Abstract

Dendritic cells (DC) have the unique ability to capture microorganisms and activate naive T lymphocytes. Obtaining DC derived from progenitors demands high cost and prolonged cultivation. Different immortalized DC has been isolated but most of them have immature phenotype and depending on growing factors or other stimuli to be used. In this study we characterized the cell line AP284 as a DC. AP284 cells express high levels of CD11b, MHC class II, 33D1 and CD209b. They also express high amounts of CD80 costimulatory molecule and different toll like receptors (TLR). After stimuli with TLR agonist they produce surprising amount of IL-12p40 related to IL-23 formation but not IL-12p70. They are also able to produce IL-6 and favor amplification of a Th17 but not Th1 profile. This DC line may be useful for a better understanding of factors and cellular interactions responsible for the induction of IL-12p40, IL-23 and Th17 generation.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IL-12p40; IL-23; Immortalized dendritic cell; Th17; Toll like receptor

Mesh:

Substances:

Year:  2019        PMID: 30773217     DOI: 10.1016/j.cellimm.2019.02.003

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  2 in total

1.  Plasmodium yoelii 17XL infection modified maturation and function of dendritic cells by skewing Tregs and amplificating Th17.

Authors:  Guang Chen; Ji-Wei Du; Qing Nie; Yun-Ting Du; Shuang-Chun Liu; De-Hui Liu; Hui-Ming Zhang; Fang-Fang Wang
Journal:  BMC Infect Dis       Date:  2020-04-06       Impact factor: 3.090

2.  TSLP Produced by Aspergillus fumigatus-Stimulated DCs Promotes a Th17 Response Through the JAK/STAT Signaling Pathway in Fungal Keratitis.

Authors:  Fang Han; Hui Guo; Leyi Wang; Yuting Zhang; Lin Sun; Chenyang Dai; Xinyi Wu
Journal:  Invest Ophthalmol Vis Sci       Date:  2020-12-01       Impact factor: 4.799

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.